Chemistry:Linepemat
Linepemat (INN), also known as 3-(2,3-difluorophenoxy)azetidine, is a drug described as a "nootrope".[1][2][3] It has been found to produce hyperlocomotion in rodents as well as to dose-dependently reverse the hypolocomotion induced by the monoamine depleting agent tetrabenazine in rodents.[2] The drug was patented by Integrative Research Laboratories (IRL) in January 2025 with the application of treatment of apathy[2][3] and its INN was registered in January 2026.[1] IRL is developing a drug with the developmental code name IRL757 for treatment of apathy in Parkinson's disease and neurodegenerative disorders.[4][5][6][7][8][9] As of January 2026, IRL757 is in phase 1/2 clinical trials for Parkinson's disease and phase 1 trials for neurodegenerative disorders, having entered phase 1/2 trials by December 2025.[4] Linepemat is very similar in chemical structure to pirepemat (IRL752), another IRL drug candidate.[2]
See also
- Motivation-enhancing drug
- Mesdopetam (IRL790)
References
- ↑ 1.0 1.1 "Proposed INN: List 134 International Nonproprietary Names for Pharmaceutical Substances (INN)". WHO Drug Information 39 (4): 1217–1218. 2025. https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl134.pdf.
- ↑ 2.0 2.1 2.2 2.3 Waters N, "3-(2,3-difluorophenoxy)azetidine, or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of pathological apathy", WO patent 2025/008506A1, published 5 July 2024
- ↑ 3.0 3.1 Kazačonok G, Ekawa B, Fernandez A, Buksa M, Nguyen L, Waters N, "Pharmaceutically acceptable salts of 3-(2,3-difluorophenoxy)azetidine and uses thereof", WO patent 2025/008504, published 9 January 2025
- ↑ 4.0 4.1 "IRL 757". AdisInsight. Springer Nature Switzerland AG. 8 January 2026. https://adisinsight.springer.com/drugs/800069085.
- ↑ "Delving into the Latest Updates on IRL-757 with Synapse". 8 May 2025. https://synapse.patsnap.com/drug/561d8ec682014921ab26cbcef5cdefdc.
- ↑ "IRL-757 Drug Profile". 1 January 1900. https://pryzm.ozmosi.com/product/27023.
- ↑ "Apathy treatment IRL757 found safe in multiple doses". 30 May 2025. https://parkinsonsnewstoday.com/news/apathy-treatment-irl757-found-safe-multiple-doses/.
- ↑ "New Parkinson's drugs targeting apathy, falls, are advancing". 3 November 2025. https://parkinsonsnewstoday.com/news/irlab-advancing-development-new-parkinsons-drugs-targeting-apathy-falls/.
- ↑ "Drug candidate for apathy enters Phase I trials". 30 May 2024. https://www.ddw-online.com/drug-candidate-for-apathy-enters-phase-i-trials-29935-202405/.
 |  |
